The Modern Age of POEM: the Past, Present and Future of Per-Oral Endoscopic Myotomy.
Kelly R Haisley, Lee L Swanström
https://pubmed.ncbi.nlm.nih.gov/33140317/Actively Recruiting
Led by Chinese University of Hong Kong · Updated on 2026-02-12
73
Participants Needed
2
Research Sites
26 weeks
Total Duration
Achalasia is a disorder where the esophagus has trouble moving food down because the lower esophageal sphincter LES does not relax properly. Patients often experience worsening swallowing difficulties, along with symptoms like nighttime cough, heartburn, weight loss, and food regurgitation. Diagnosis usually involves tests like esophageal imaging, endoscopy, and manometry, with the Eckardt Symptom Score ESS used to judge the severity and treatment effect. This trial aims to assess a new device designed to improve a minimally invasive treatment called per-oral endoscopic myotomy POEM in patients with achalasia. The study evaluates the safety and effectiveness of a novel SpydrBlade Flex device, which uses radiofrequency and microwave ablation technology for the POEM procedure. This device may be used with either the anterior or posterior POEM approach, depending on the patients condition and the doctors preference. The treatment involves creating a tunnel in the esophagus lining and cutting muscle to reduce LES pressure, helping food pass into the stomach more easily. Participants will undergo the POEM procedure using this new device. Researchers will monitor several outcomes, including the technical success of the procedure within one day and clinical symptom improvement after 30 days. Safety will be tracked by noting any complications during and after the operation. Additional assessments of reflux symptoms, esophageal function, and quality of life will be done up to six months post-procedure. The total study duration allows for follow-up to ensure safety and measure longer-term effects.
CONDITIONS
Safety and Efficacy of a Novel SpydrBlade Flexible Bipolar in POEM
H
Hon Chi Yip
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Chinese University of Hong Kong
Lead Sponsor
Academy tertiary center, IECED, Guayaquil, Ecuador
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 day
Participants undergo Per-Oral Endoscopic Myotomy (POEM) using the novel SpydrBlade Flex device.
1 visit (procedure day)
Duration - 30 days
Participants are monitored for clinical success and complications after the procedure. Additional assessments include symptom evaluation and pH monitoring related to post-procedural reflux.
1 to 2 visits depending on assessments
Duration - 6 months
Participants complete further evaluations including endoscopic features, lower esophageal sphincter distensibility, and quality of life assessments related to post-procedural reflux.
1 to 2 visits during this period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Kelly R Haisley, Lee L Swanström
https://pubmed.ncbi.nlm.nih.gov/33140317/Faisal Kamal, Mohammad K Ismail, Muhammad A Khan...
https://pubmed.ncbi.nlm.nih.gov/33654353/Bailey Su, Zachary M Callahan, Stephanie Novak...
https://pubmed.ncbi.nlm.nih.gov/31939098/Lars Lundell
https://pubmed.ncbi.nlm.nih.gov/32919412/Sabrina Drexel, Sami Kishawi, Jeffrey Marks
https://pubmed.ncbi.nlm.nih.gov/33128887/Pravallika Chadalavada, Prashanthi N Thota, Siva Raja...
https://pubmed.ncbi.nlm.nih.gov/33173323/Yahya Ahmed, Mohamed O Othman
https://pubmed.ncbi.nlm.nih.gov/31489229/Roberto Oleas, Miguel Puga-Tejada, María Sánchez-Carriel...
https://pubmed.ncbi.nlm.nih.gov/36502466/Manabu Onimaru, Haruhiro Inoue, Yusuke Fujiyoshi...
https://pubmed.ncbi.nlm.nih.gov/33655041/Fraukje A Ponds, Paul Fockens, Aaltje Lei...
https://pubmed.ncbi.nlm.nih.gov/31287522/Chinese University of Hong Kong
Lead Sponsor
Academy tertiary center, IECED, Guayaquil, Ecuador
Collaborating Sponsor